SG3185G - Compositions containing 1,3-dimethyl-5-aminoadamantane - Google Patents

Compositions containing 1,3-dimethyl-5-aminoadamantane

Info

Publication number
SG3185G
SG3185G SG31/85A SG3185A SG3185G SG 3185 G SG3185 G SG 3185G SG 31/85 A SG31/85 A SG 31/85A SG 3185 A SG3185 A SG 3185A SG 3185 G SG3185 G SG 3185G
Authority
SG
Singapore
Prior art keywords
aminoadamantane
dimethyl
compositions containing
compositions
Prior art date
Application number
SG31/85A
Other languages
English (en)
Original Assignee
Merz & Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz & Company filed Critical Merz & Company
Publication of SG3185G publication Critical patent/SG3185G/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG31/85A 1978-12-27 1985-01-11 Compositions containing 1,3-dimethyl-5-aminoadamantane SG3185G (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2856393A DE2856393C2 (de) 1978-12-27 1978-12-27 Arzneimittel zur Behandlung von Morbus Parkinson

Publications (1)

Publication Number Publication Date
SG3185G true SG3185G (en) 1985-06-14

Family

ID=6058522

Family Applications (1)

Application Number Title Priority Date Filing Date
SG31/85A SG3185G (en) 1978-12-27 1985-01-11 Compositions containing 1,3-dimethyl-5-aminoadamantane

Country Status (10)

Country Link
US (1) US4273774A (fr)
JP (1) JPS5589219A (fr)
BE (1) BE880905A (fr)
CA (1) CA1121726A (fr)
DE (1) DE2856393C2 (fr)
FR (1) FR2445145A1 (fr)
GB (1) GB2044098B (fr)
NL (1) NL7909307A (fr)
SE (1) SE448517B (fr)
SG (1) SG3185G (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33080E (en) * 1981-08-31 1989-10-03 Exxon Research And Engineering Company Adamantane catalyzed paraffin isomerization
US5506231A (en) * 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5455279A (en) * 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5614560A (en) * 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
CN100339070C (zh) 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
UA80055C2 (en) * 2003-05-27 2007-08-10 Forest Laboratories Combination of nmda-receptor antagonist and selective inhibitor of serotonin reuptake for a depression and other pscihiatric disorders treatment
BRPI0411451A (pt) * 2003-06-16 2006-07-18 Allergan Inc formas de dosagens orais de memantina
AU2004316119B2 (en) * 2003-10-22 2008-04-24 Merz Pharma Gmbh & Co. Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic AB peptides in amyloidopathies
AR046314A1 (es) 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
SI1703902T1 (sl) * 2004-01-05 2011-02-28 Merz Pharma Gmbh & Co Kgaa Memantin za zdravljenje blage do zmerne Alzheimerjeve bolezni
US7456224B2 (en) * 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
WO2006009769A1 (fr) * 2004-06-17 2006-01-26 Forest Laboratories, Inc. Formulation de liberation modifiee de memantine
BRPI0512263A (pt) 2004-06-17 2008-02-26 Merz Pharma Gmbh & Co Kgaa formulações de liberação imediata de formas de dosagem oral de memantina
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US20060079582A1 (en) * 2004-09-23 2006-04-13 Jeffrey Jonas Memantine for the treatment of childhood behavioral disorders
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EA013474B1 (ru) * 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
EP2040676A2 (fr) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Formulations à dissolution orale de mémantine
TW200823215A (en) 2006-08-04 2008-06-01 Merz Pharma Gmbh & Amp Co Kgaa Pyrazolopyrimidines, a process for their preparation and the use as a medicine
WO2008063847A2 (fr) * 2006-11-03 2008-05-29 Forest Laboratories Holdings Limited Méthode de traitement de l'autisme
EP2090576A1 (fr) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, leur procédé de préparation et leur utilisation en tant que modulateurs des récepteurs metabotropiques du glutamate (mGluR)
EP2085398A1 (fr) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, leur procédé de préparation et leur utilisation en tant que médicament
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2111858A1 (fr) 2008-04-25 2009-10-28 EPFL Ecole Polytechnique Fédérale de Lausanne Nouveau traitement pour la maladie d'Alzheimer
US20090275597A1 (en) * 2008-05-02 2009-11-05 Forest Laboratories Holdings Limited Methods of treating cns disorders
EP2138173A1 (fr) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Compositions pharmaceutiques comportant des dérivés d'aminoadamantane
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ, インコーポレイテッド アマンタジン組成物および使用方法
US20110251239A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
WO2012052451A1 (fr) 2010-10-18 2012-04-26 Merz Pharma Gmbh & Co. Kgaa Modulateurs des récepteurs métabotropes au glutamate
JP5848768B2 (ja) 2010-10-29 2016-01-27 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドRamot At Tel Aviv University Ltd. インドール誘導体及びその製造方法
AU2011328993B2 (en) 2010-11-15 2017-03-02 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
AR084515A1 (es) 2010-12-22 2013-05-22 Merz Pharma Gmbh & Co Kgaa Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras
WO2012085166A1 (fr) 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Modulateurs des récepteurs glutamatergiques métabotropes
WO2012152854A1 (fr) 2011-05-12 2012-11-15 Merz Pharma Gmbh & Co. Kgaa Modulateurs de récepteur de glutamate métabotropique
WO2012172093A1 (fr) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dérivé de dihydroindolizine à titre de modulateurs des récepteurs métabotropes de glutamate
EP2650284A1 (fr) 2012-04-10 2013-10-16 Merz Pharma GmbH & Co. KGaA Dérivés hétérocycliques comme modulateurs de récepteurs du glutamate métabotropique
RU2488388C1 (ru) 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
DK2892540T3 (en) * 2012-09-06 2018-11-19 Mcpharma Biotech Inc TREATMENT OF DIARRES AND DRAWN DIARRES WITH RESISTANT POTATO STARCH
WO2014204933A1 (fr) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Compositions d'amantadine et procédés d'utilisation
EP4032889B1 (fr) 2013-12-20 2026-05-06 Agenebio, Inc. Dérivés de benzodiazépine, compositions et méthodes de traitement de déficience cognitive
CA2938671A1 (fr) 2014-02-04 2015-08-13 Forest Laboratories Holdings Limited Compositions de donepezil et procede de traitement de la maladie d'alzheimer
EP3310785B1 (fr) 2015-06-19 2024-11-20 Agenebio, Inc. Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
US10835499B2 (en) 2015-12-30 2020-11-17 Corium, Inc. Systems and methods for long term transdermal administration
CN109922796B (zh) 2016-06-23 2023-04-07 考里安有限责任公司 具有亲水和疏水域的粘合剂基质和治疗剂
KR102424270B1 (ko) 2016-07-27 2022-07-25 코리움, 인크. 경구 전달과 생물학적으로 동등한 약물동역학을 가진 경피 전달 시스템
EP3490544A1 (fr) 2016-07-27 2019-06-05 Corium International, Inc. Systèmes d'administration transdermique de mémantine
JP7071330B2 (ja) 2016-07-27 2022-05-18 コリウム, インコーポレイテッド 炭酸水素ナトリウムのin situ変換で促進されたアミン薬物の経皮送達
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
WO2019126531A1 (fr) 2017-12-20 2019-06-27 Corium, Inc. Composition adhésive transdermique comprenant un agent thérapeutique liquide volatil à bas point de fusion
AU2019288382B2 (en) 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP4475953A1 (fr) 2022-02-08 2024-12-18 Fikret SAHIN Antagonistes nmdar prévenant le vieillissement et les troubles et maladies associées au vieillissement en augmentant l'activité du protéasome 20s
EP4572852A1 (fr) 2022-08-19 2025-06-25 Agenebio, Inc. Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3864489A (en) * 1972-03-20 1975-02-04 Gen Foods Corp Treatment of hyperkinetic conditions with caffeine
NL7305644A (fr) * 1972-04-20 1973-10-23
AU6889274A (en) * 1973-05-17 1975-11-20 Astra Laekemedel Ab Treatment of neurological disorders
DE2518677A1 (de) * 1974-05-06 1975-11-20 Sandoz Ag Neue pharmazeutische zubereitungen

Also Published As

Publication number Publication date
DE2856393A1 (de) 1980-07-03
FR2445145A1 (fr) 1980-07-25
GB2044098A (en) 1980-10-15
CA1121726A (fr) 1982-04-13
BE880905A (fr) 1980-06-27
NL7909307A (nl) 1980-07-01
FR2445145B1 (fr) 1984-10-26
GB2044098B (en) 1983-01-26
DE2856393C2 (de) 1983-04-28
US4273774A (en) 1981-06-16
JPS5589219A (en) 1980-07-05
SE448517B (sv) 1987-03-02
SE7910501L (sv) 1980-06-28

Similar Documents

Publication Publication Date Title
GB2044098B (en) Compositions comprising 1,3-dimethyl-5-aminoadamantane
JPS54139654A (en) Composition
GB2011917B (en) Rubber compositions containing 1,2-polybutadience
IL60491A0 (en) 2,2-difluoro-6a-carba-pgi2 compounds
IL57923A (en) 1,2,3,5-tetrahydroimidazothienopyrimidin-2-ones
PH15420A (en) 1,2,4-5-tetra-alkyl-4-arylpiperidines
PH15791A (en) Pharmaceutical composition containing 3,4-dihydro-3-oxoquinoxalines
JPS54152038A (en) Flameeproof*lowwsmoke hottmelt composition
JPS54107993A (en) Alphaacyanoacrylate composition
GB2034704B (en) 2,6-daiminonebularines
JPS54147931A (en) Antiiulcer composition
GR64915B (en) Improved etomidate-containing compositions
GR64830B (en) Disinfectaut composition
PT69935A (en) Insecticidals compositions
IL56443A0 (en) 2,6-dinitrobenzeneamines
GB2087873B (en) 1,2-dioximes
GB2021108B (en) 6,7 - di - 4 - amino - 2 - quinazolines
PT69225A (en) Compositions
ZA793302B (en) Fasciolicidal compositions
PH17142A (en) 6,7-benzomorphans
JPS54147934A (en) Antiiangina composition
GB2018769B (en) 2,3-dihydro-4h-1-benzopyran-4-one o-carbamoyl-oximes
PT70100A (en) Farmaceutical compositions
GB2026861B (en) Pharmaceutical compositions containing 5-methyl-7-diethylamino-s-triazolo (1,5- )-pyrimidine
GB2032431B (en) 2,3 - dimethyl - pent - 4en - aldehyde